The following is an excerpt from an article by Robert Lowe in the latest edition of TechInsight.
When I first joined a technology transfer office at the University of California in 1999, >80% of the licenses signed were with large companies. The remaining licenses were divided between start-ups emerging from the university and the occasional small firm.
Today, that script has flipped.
Many tech transfer offices are taking a “start-up first” approach. This shift is reshaping tech transfer operations across the globe. This month we spoke with three leaders who build start-ups for a living inside universities: Dave Repp at the University of Michigan, home of the Accelerate Blue Foundry; Darya Bubman, who leads a start-up development team at University of California San Francisco (UCSF); and Greg Markiewicz, New Ventures Principal at Washington University (WASHU) in St. Louis. Their programs differ, but their lessons overlap.
All three point first to industry. Pharma companies “want more derisking now, even through phase 2, so they’re waiting,” Repp said.
Markiewicz also noted that many large companies’ research departments have seen significant reductions in budgets, causing many companies to place resources on later-stage technologies.
Demand for start-up opportunities is also rising inside universities. Entrepreneurship has become a popular subject on campus, Markiewicz said, and he notes that many faculty are encouraged to start a company as part of their path to tenure. Cuts to federal agency funding are also pushing more faculty to consider SBIR, ARPA-H and similar programs to keep their labs going.
Is the start-up boom driving universities to build ventures programs, or are the programs creating the boom? “It is probably a little bit of both,” Repp said.
Triage Early, and Let the Market Weigh in
Until about six years ago, Bubman said, UCSF was doing “tech transfer 101”: file a patent, then try to market it. Today her team runs a market-first assessment of every invention before deciding where to spend limited resources. The team only has four people and receives about 250 disclosures a year, requiring them to leverage resources and expertise around them to make go-no go decisions with incoming disclosures.
Market research tools help. The team once relied on several market research platforms and now increasingly uses AI, including ChatGPT and TradeSpace. Bubman said AI is particularly good at surfacing biotech-to-biotech deals and M&A activity. “But nothing can really replace the real feedback from VCs,” she said.
Read the full article.